Impact of Age and Colony-Stimulating Factor Use on Hospital Length of Stay for Febrile Neutropenia in CHOP-Treated Non-Hodgkin's Lymphoma

Abstract

Background

In intermediate-grade non-Hodgkin's lymphoma (NHL) patients, full-dose CHOP improves survival but increases myelosuppression, causing febrile neutropenia hospitalization (FNH) in 28% of patients 65 years of age or greater. Several risk factors for FNH are known, but their relationship to length of stay (LOS), an indicator of the total burden of FNH, is unclear.

Methods

We conducted a study to identify factors associated with the incidence, recurrence, and duration of hospitalizations for FN and to describe the frequency of administration of colony-stimulating factor (CSF) as primary and secondary prophylaxis and its association with repeated hospitalization episodes.

Results

Compared with patients who did not experience hospitalizations for FN, those who did were significantly older, had more comorbid conditions, were planned for standard dose intensity, and received CSF less often during the first 5 days of cycle 1 (early CSF). Overall, 73% of these hospitalizations occurred within the first 2 cycles of chemotherapy, with 56% occurring within the first cycle. Patients age ≥65 years accounted for 66% of cycle 1 FNH. Patients receiving early CSF were less likely to experience repeated hospitalizations (0% vs 12%; P.05). Multiple regression analysis of those hospitalized found a 3.9-day longer LOS for patients age ≥65 years and a 5.13-day longer LOS for those not receiving early CSF.

Conclusions

Older NHL patients have a higher risk of hospitalization for FN and longer LOS. The majority of hospitalization days occur in the first 2 cycles of chemotherapy. Early CSF use is associated with decreased risk of repeated hospitalizations and shorter total LOS. Secondary CSF use is also associated with reduced risk of repeated FNH.

References

Wingo

P.A.

, Ries

L.A.

, Giovino

G.A.

. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999; 91: 675–690.

Greenlee

R.T.

, Hill-Harmon

M.B.

, Murray

. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23–47.

Glass

A.G.

, Karnell

L.H.

, Menck

H.R.

. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer. 1997; 80: 2311–2320.

Fisher

R.I.

, Gaynor

E.R.

, Dahlberg

. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 1002–1006.

Coltman

C.A.

, Dahlberg

, Jones

S.E.

. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: Skarin

A.T.

, ed. Update on Treatment for Diffuse Large Cell Lymphoma. New York, NY: Park Row; 1986: 71–77.

McKelvey

E.M.

, Gottlieb

J.A.

, Wilson

H.E.

. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976; 38: 1484–1493.

Tirelli

, Errante

, Van Glabbeke

. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 27–34.

Dixon

D.O.

, Neilan

, Jones

S.E.

. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986; 4: 295–305.

Epelbaum

, Haim

, Ben-Shahar

. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci. 1988; 24: 533–538.

10.

Kwak

L.W.

, Halpern

, Olshen

R.A.

. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963–977.

11.

Lepage

, Gisselbrecht

, Haioun

. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 1993; 4: 651–656.

12.

Gaynor

E.R.

, Dahlberg

, Fisher

R.I.

. Factors affecting reduced survival of the elderly with intermediate grade lymphoma: an analysis of SWOG-8516(INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B. Proc Annu Meet Am Soc Clin Oncol. 1994; 13: 1250. Abstract.

13.

Armitage

J.O.

, Potter

J.F.

. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984; 32: 269–273.

14.

Gomez

, Hidalgo

, Casanova

. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998; 16: 2065–2069.

15.

Donnelly

G.B.

, Glassman

, Long

. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcomes in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Leuk Lymphoma. 2000; 39: 67–75.

16.

Crawford

, Ozer

, Stoller

. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164–170.

17.

Ohno

, Tomonaga

, Kobayashi

. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med. 1990; 323: 871–877.

18.

Gabrilove

J.L.

, Jakubowski

, Scher

. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988; 318: 1414–1422.

19.

Bronchud

, Scarffe

J.H.

, Thatcher

. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987; 56: 809–813.

20.

Jacobson

J.O.

, Grossbard

, Shulman

L.N.

. CHOP chemotherapy with G-CSF in elderly patients with intermediate grade lymphoma (IGL): full dose intensity is possible. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 41. Abstract.

21.

Zinzani

P.L.

, Pavone

, Storti

. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997; 89: 3974–3979.

22.

Zinzani

P.L.

, Storti

, Zaccaria

. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999; 94: 33–38.

23.

Bjorkholm

, Osby

, Hagberg

. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Blood. 1999; 94: 2665. Abstract.

24.

Morrison

V.A.

, Picozzi

, Scott

. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001; 2: 47–56.

25.

Charlson

M.E.

, Pompei

, Ales

K.L.

. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: 373–383.

26.

Deyo

R.A.

, Cherkin

D.C.

, Ciol

M.A.

. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613–619.

27.

Romano

P.S.

, Roos

L.L.

, Jollis

J.G.

. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol. 1993; 46: 1075–1079; discussion: 1081-1090.

28.

Carbone

P.P.

, Kaplan

H.S.

, Musshoff

. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 1860–1861.

29.

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage.

The Non-Hodgkin's Lymphoma Pathologic Classification Project.

Cancer. 1982; 49: 2112–2135.

30.

Hryniuk

, Bush

. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2: 1281–1288.

31.

Balducci

. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control. 2001; 8(2 suppl): 1–25.

32.

Martelli

, De Sanctis

, Avvisati

. Current guidelines for the management of aggressive non-Hodgkin's lymphoma. Drugs. 1997; 53: 957–972.

33.

Niitsu

. Non-Hodgkin's lymphoma in the elderly: a guide to treatment. Drugs Aging. 1999; 14: 447–457.

34.

Rubenstein

L.Z.

, Stuck

A.E.

, Siu

A.L.

. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc. 1991; 39: 8S–16S.

35.

Blayney

D.W.

, Williams

, Mortimer . J. NEUPOGEN® (r-metHuG-CSF) ameliorates neutropenia during CHOP chemotherapy. Proc Annu Meet Am Soc Clin Oncol. 1992; 11: 1088. Abstract.

36.

American Society of Clinical Oncology.

Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

J Clin Oncol. 1994; 12: 2471–2508.

37.

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidenced-based clinical practice guidelines.

American Society of Clinical Oncology.

J Clin Oncol. 1996; 14: 1957–1960.

38.

Ozer

, Armitage

J.O.

, Bennett

C.L.

. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000; 18: 3558–3585.

39.

Balducci

, Hardy

C.L.

, Lyman

G.H.

. Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol. 2001; 8: 170–187.

40.

Balducci

. Geriatric oncology: challenges for the new century. Eur J Cancer. 2000; 36: 1741–1754.